Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1 Background and Objective Allergic and atopic diseases—including atopic dermatitis (AD), IgE-mediated food allergy (FA), allergic rhinitis (AR), and allergic asthma (AA)—are among the most common chronic conditions in childhood and adolescence. Together, they constitute a major group of noncommunicable diseases that have increased substantially in prevalence over the past decades, particularly in industrialized and urbanized regions.
Allergen immunotherapy (AIT) is a safe, effective treatment for allergic rhinoconjunctivitis and allergic asthma. However, AIT's clinical effect is still contested—primarily due to heterogeneity in clinical trial designs, study populations, therapeutic formulations, and efficacy criteria.
Allergen immunotherapy (AIT) is a safe, effective treatment for allergic rhinoconjunctivitis and allergic asthma. However, AIT's clinical effect is still contested - primarily due to heterogeneity in clinical trial designs, study populations, therapeutic formulations and efficacy criteria.
The vision of European Academy of Allergy and Clinical Immunology (EAACI) and the Union of European Medical Specialists Section and Board on allergology is to promote and to establish a full specialty of allergology in all European countries. In many European countries, a full specialty does not exist. In those countries, organ‐based (sub)specialists or paediatricians and internists with an expertise in allergology may deliver allergy care.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
